ATE217347T1 - Diagnose mittels signalverstärkung durch ein ribozym - Google Patents

Diagnose mittels signalverstärkung durch ein ribozym

Info

Publication number
ATE217347T1
ATE217347T1 AT94903451T AT94903451T ATE217347T1 AT E217347 T1 ATE217347 T1 AT E217347T1 AT 94903451 T AT94903451 T AT 94903451T AT 94903451 T AT94903451 T AT 94903451T AT E217347 T1 ATE217347 T1 AT E217347T1
Authority
AT
Austria
Prior art keywords
target
ribozyme
bound
molecule
image
Prior art date
Application number
AT94903451T
Other languages
English (en)
Inventor
Andy Shih
Jeffrey M Bockman
Shaji T George
Original Assignee
Univ Yale
Ribozyme Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Ribozyme Pharm Inc filed Critical Univ Yale
Application granted granted Critical
Publication of ATE217347T1 publication Critical patent/ATE217347T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Road Signs Or Road Markings (AREA)
  • Amplifiers (AREA)
  • Dental Preparations (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Stereo-Broadcasting Methods (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT94903451T 1992-12-04 1993-12-03 Diagnose mittels signalverstärkung durch ein ribozym ATE217347T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98530892A 1992-12-04 1992-12-04
PCT/US1993/011775 WO1994013833A1 (en) 1992-12-04 1993-12-03 Ribozyme amplified diagnostics

Publications (1)

Publication Number Publication Date
ATE217347T1 true ATE217347T1 (de) 2002-05-15

Family

ID=25531365

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903451T ATE217347T1 (de) 1992-12-04 1993-12-03 Diagnose mittels signalverstärkung durch ein ribozym

Country Status (8)

Country Link
US (1) US5589332A (de)
EP (2) EP0681613B1 (de)
JP (2) JP3595841B2 (de)
AT (1) ATE217347T1 (de)
AU (1) AU675482B2 (de)
DE (1) DE69331911T2 (de)
ES (1) ES2176233T3 (de)
WO (1) WO1994013833A1 (de)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081494A1 (en) * 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US20030125270A1 (en) * 2000-12-18 2003-07-03 Lawrence Blatt Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
WO1995003427A2 (en) * 1993-07-19 1995-02-02 Gen-Probe Incorporated Oligonucleotide screening assay
AU692212B2 (en) * 1993-12-17 1998-06-04 Roger S. Cubicciotti Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5998193A (en) * 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US6214546B1 (en) 1995-02-27 2001-04-10 Intelligene Ltd. Detection of biomolecules
AU697317B2 (en) * 1995-02-27 1998-10-01 Intelligene Ltd. Detection of biomolecules
RU2139352C1 (ru) * 1995-02-27 1999-10-10 Интеллиджин Лтд. Обнаружение биомолекул
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US7034009B2 (en) * 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US5985557A (en) 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
DK1634890T3 (da) * 1996-01-24 2009-03-09 Third Wave Tech Inc Invasiv klövning af nukleinsyrer
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
AU3299997A (en) * 1996-06-10 1998-01-07 Wang, Fennggang Method for randomly synthesizing biopolymers
DE69735684T2 (de) * 1996-08-26 2007-04-05 Genetico Ltd. Katalytische Nukleinsäure und deren medizinische Verwendung
WO1998027104A1 (en) * 1996-12-19 1998-06-25 Yale University Bioreactive allosteric polynucleotides
US20030186909A1 (en) * 1997-01-27 2003-10-02 Ribozyme Pharmaceuticals, Inc. Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
EP2327797B1 (de) * 1997-04-01 2015-11-25 Illumina Cambridge Limited Verfahren zur Vervielfältigung von Nukleinsäuren
US6194149B1 (en) * 1998-03-03 2001-02-27 Third Wave Technologies, Inc. Target-dependent reactions using structure-bridging oligonucleotides
WO1999009045A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
EP1053317B1 (de) 1998-02-13 2006-11-02 Köster, Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
JP4318856B2 (ja) * 1998-03-05 2009-08-26 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド チモーゲン性核酸検出方法、および関連分子およびキット
AU3707099A (en) * 1998-04-08 1999-11-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Process for producing cell clone libraries
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6995259B1 (en) * 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
IL126731A0 (en) * 1998-10-23 1999-08-17 Intelligene Ltd A method of detection
IL126732A0 (en) * 1998-10-23 1999-08-17 Intelligene Ltd Pro drug
DE19915141C2 (de) * 1999-03-26 2002-11-21 Artus Ges Fuer Molekularbiolog Detektion von Nucleinsäure-Amplifikaten
IL130606A0 (en) * 1999-06-23 2000-06-01 Intelligene Ltd An array of nucleic acid sequence
IL132710A0 (en) * 1999-11-02 2001-03-19 Intelligene Ltd Catalytic nucleic acid sequences
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
EP1265995A2 (de) * 2000-02-11 2002-12-18 Ribozyme Pharmaceuticals, Inc. Verfahren und reagenzien zur modulation und diagnose der expression von den cd20 und nogo genen
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
AU4345401A (en) * 2000-03-06 2001-09-17 Ribozyme Pharmaceuticals, Inc. Nucleic acid sensor molecules
US20040009510A1 (en) * 2000-03-06 2004-01-15 Scott Seiwert Allosteric nucleic acid sensor molecules
US20030065155A1 (en) * 2000-03-06 2003-04-03 Nassim Usman Nucleic acid sensor molecules
WO2001096541A2 (en) * 2000-06-15 2001-12-20 Board Of Regents Allosterically regulated ribozymes
WO2001096559A2 (en) * 2000-06-15 2001-12-20 Board Of Regents The University Of Texas System Regulatable, catalytically active nucleic acids
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US7125660B2 (en) * 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
AR031640A1 (es) * 2000-12-08 2003-09-24 Applied Research Systems Amplificacion isotermica de acidos nucleicos en un soporte solido
US20050014172A1 (en) * 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050233996A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050124568A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050164224A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050137155A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050130181A1 (en) * 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20050124567A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050054598A1 (en) * 2002-02-20 2005-03-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) * 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20030130186A1 (en) * 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050182006A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20060142226A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
AU2002316135B9 (en) 2001-05-18 2009-05-28 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050164966A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1390472A4 (de) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
AU2002313699A1 (en) * 2001-07-20 2003-03-03 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
WO2003014375A2 (en) * 2001-08-09 2003-02-20 Archemix Corporation Nucleic acid sensor molecules and methods of using same
US8512953B2 (en) * 2001-09-24 2013-08-20 One Lambda Diagnostic probe detection system
WO2003057709A2 (en) * 2001-10-19 2003-07-17 Sirna Therapeutics, Inc Method and reagent for the detection of proteins and peptides
US20030219775A1 (en) * 2001-12-14 2003-11-27 Ward David C. Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
US7122314B2 (en) * 2002-01-30 2006-10-17 Id Biomedical Corporation Methods for detecting vancomycin-resistant microorganisms and compositions therefor
US20050042632A1 (en) * 2002-02-13 2005-02-24 Sirna Therapeutics, Inc. Antibodies having specificity for nucleic acids
US7071311B2 (en) * 2002-02-13 2006-07-04 Sirna Therapeutics, Inc. Antibodies having specificity for 2′-C-allyl nucleic acids
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
WO2003106476A1 (en) * 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20040018515A1 (en) * 2002-04-03 2004-01-29 Diener John L. Compositions selective for adenosine diphosphate and methods of using same
US20030228603A1 (en) * 2002-04-05 2003-12-11 Cload Sharon T. Compositions selective for caffeine or aspartame and methods of using same
US20030224435A1 (en) * 2002-05-16 2003-12-04 Scott Seiwert Detection of abused substances and their metabolites using nucleic acid sensor molecules
AU2003253651C1 (en) * 2002-06-14 2010-06-03 Gen-Probe Incorporated Compositions and methods for detecting hepatitis B virus
CA2487809A1 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
JP2005533862A (ja) 2002-07-25 2005-11-10 アーケミックス コーポレイション 調節されたアプタマー治療剤
US20040137429A1 (en) * 2002-10-02 2004-07-15 David Epstein Therapeutic aptamers having binding specificity to gp41 of HIV
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
AU2003296946A1 (en) * 2002-12-12 2004-07-09 Chiron Corporation A biological sample storage device and method for biological sample contamination testing
US20040231231A1 (en) * 2002-12-20 2004-11-25 Cataldo Dominic A. Use of colloidal clays for sustained release of active ingredients
US20030232400A1 (en) * 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
EP1622572B1 (de) 2003-04-30 2017-12-20 Sirna Therapeutics, Inc. Konjugate und zusammensetzungen für die zelluläre abgabe
JPWO2005028647A1 (ja) * 2003-09-22 2006-11-30 国立大学法人京都大学 核酸プローブ、核酸チップ、標的核酸検出方法、薬剤スクリーニング方法、標的核酸検出装置及び遺伝子診断方法
WO2005073405A2 (en) * 2004-01-29 2005-08-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Catalytic polynucleotide and its use for determination of analytes
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
CN103789311A (zh) * 2005-10-07 2014-05-14 强生研究有限公司 多组分核酸酶及其使用方法
GB0522310D0 (en) 2005-11-01 2005-12-07 Solexa Ltd Methods of preparing libraries of template polynucleotides
GB0524069D0 (en) * 2005-11-25 2006-01-04 Solexa Ltd Preparation of templates for solid phase amplification
US8097425B2 (en) * 2006-03-10 2012-01-17 Tethys Bioscience, Inc. Multiplex protein fractionation
EP2021503A1 (de) * 2006-03-17 2009-02-11 Solexa Ltd. Isothermische methoden zur entstehung von arrays von einzelnen molekülen
US7955443B2 (en) 2006-04-14 2011-06-07 Shin-Etsu Chemical Co., Ltd. Method for preparing rare earth permanent magnet material
CN101479375B (zh) 2006-05-03 2016-03-30 科罗拉多州立大学董事会 Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
EP2471809B1 (de) 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteine, Nukleinsäuren zu deren Kodierung und entsprechende Verwendungsverfahren
EP2066817B1 (de) * 2006-10-06 2014-07-30 SpeeDx Pty Ltd Molekulare schalter und verfahren zu deren verwendung
EP2121983A2 (de) 2007-02-02 2009-11-25 Illumina Cambridge Limited Verfahren zur kennzeichnung von proben und sequenzierung mehrerer nukleotidmatrizen
KR101583834B1 (ko) * 2007-04-05 2016-01-19 존슨 앤드 존슨 리서치 피티와이 리미티드 핵산 효소 및 복합체 및 이의 사용 방법
US8728764B2 (en) * 2008-10-02 2014-05-20 Illumina Cambridge Limited Nucleic acid sample enrichment for sequencing applications
US20100305197A1 (en) * 2009-02-05 2010-12-02 Massachusetts Institute Of Technology Conditionally Active Ribozymes And Uses Thereof
US8182994B2 (en) 2009-09-15 2012-05-22 Illumina Cambridge Limited Centroid markers for image analysis of high denisty clusters in complex polynucleotide sequencing
WO2011076807A2 (en) * 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
ES2908827T3 (es) 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP3623361B1 (de) 2013-12-19 2021-08-18 Novartis AG Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US10934549B2 (en) 2017-08-18 2021-03-02 University Of Iowa Research Foundation Nucleic acid aptamers
WO2020023741A1 (en) * 2018-07-25 2020-01-30 Ohio State Innovation Foundation Large scale production of rna particles
EP4229208A4 (de) 2020-10-14 2024-10-30 George Mason Research Foundation, Inc. Verfahren zur herstellung von lipidnanopartikeln und zusammensetzungen daraus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775619A (en) * 1984-10-16 1988-10-04 Chiron Corporation Polynucleotide determination with selectable cleavage sites
ATE115999T1 (de) * 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
JP3276955B2 (ja) * 1988-09-30 2002-04-22 ジーン−トラック・システムス Ｒｎａの鋳型の末端に結合したプローブ構造およびその使用方法
NZ314629A (en) * 1991-01-17 2000-08-25 Gen Hospital Corp Use trans-splicing ribozymes to prepare medicaments for gene therapies

Also Published As

Publication number Publication date
JP3595841B2 (ja) 2004-12-02
EP0681613A4 (de) 1998-05-20
JP2004000281A (ja) 2004-01-08
JPH08507202A (ja) 1996-08-06
ES2176233T3 (es) 2002-12-01
US5589332A (en) 1996-12-31
EP1195442A3 (de) 2002-07-31
WO1994013833A1 (en) 1994-06-23
EP1195442A2 (de) 2002-04-10
DE69331911D1 (de) 2002-06-13
EP0681613B1 (de) 2002-05-08
AU675482B2 (en) 1997-02-06
DE69331911T2 (de) 2002-11-21
AU5739694A (en) 1994-07-04
EP0681613A1 (de) 1995-11-15

Similar Documents

Publication Publication Date Title
ATE217347T1 (de) Diagnose mittels signalverstärkung durch ein ribozym
NZ504818A (en) Fluorimetric detection system for nucleic acids
ATE206764T1 (de) Verfahren zum sensitiven nachweis von nukleinsäuren
ATE188745T1 (de) Verfahren zur detektion einer nukleinsaeure mittels einer nukleinsaeuresonde, das ein spezifisches einfangen und eine detektion auf einmal erlaubt
ATE191934T1 (de) Verfahren zur isothermer amplifikation von nukleinsäure molekülen
ATE188744T1 (de) Verfahren zur erhöhung der nachweisempfindlichkeit von nukleinsäure-hybriden (target/probe)
KR910009926A (ko) 연결 가능한 헤어핀 프로브와 전사를 이용한 핵산 증폭 방법
CA2076750A1 (en) Nucleic acid amplification with dna-dependent rna polymerase activity of rna replicases
EP1201771A3 (de) Erkennung und Identifizierung von menschlichen Papillomavirus mit Hilfe von PCR und Typ-spezifischer reversen Hybridisierung
ATE210734T1 (de) Verfahren zur quantifizierung von genomischer dna
ATE147791T1 (de) Festphasendiagnose von medizinischen konditionen
ATE204332T1 (de) Positionelle sequenzierung durch hybridisierung
EP0905258A3 (de) Verfahren zum Nachweis von Nukleinsäuresequenzen unter Verwendung von auf Festphasen immobilisierten Nukleotid-Sonden (line probe assay)
ATE414169T1 (de) Methoden zur detektion von nukleinsäuren unter verwendung von zymogenen und dazugehörige kits
AU653244B2 (en) Detection of complementary nucleotide sequences
DE60219813D1 (de) Test-streife-probesystem und verfahren zur nachweis von spezifischen nukleinsäuresequenzen
DE69940903D1 (de) Diagnostische methoden basierend auf katalytischen nukleinsäuren
EP0745675A3 (de) Methode zur Amplifizierung von Nukleinsäure und entsprechende Regenzien dafür
US20130244223A1 (en) Respiratory syncytial virus (rsv) viral load detection assay
EP4299759A1 (de) Nukleinsäuredetektionsverfahren
WO2005060618A3 (en) Enzyme-free isothermal exponential amplification of nucleic acids and nucleic acid analog signals
Shih et al. Ribozyme amplified diagnostics
KR960705062A (ko) Cmv 핵산 증폭 및 검출용 프라이머와 프로브(primers and probes for the amplification and detection of cmv nucleic acid)
ATE476519T1 (de) Verfahren zur synthese und amplifikation von nukleinsäuren
JP2005504308A (ja) 標的分子および分子間相互作用の検出法

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee